21165 ⎘
Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA; Animal cells expressing foreign proteins
BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
#902Induced activation in dendritic cells
#903Modified natural killer cells and natural killer cell lines having increased cytotoxicity
#904Drug regulated transgene expression
#905Complexes of IL-15 and IL-15Ralpha and uses thereof
#906DNA vector and transformed tumor cell vaccines
#907Methods of Preparing T Cells for T Cell Therapy
#908Engineered cells expressing multiple immunomodulators and uses thereof
#909Fusion molecule based on novel TAA variant
#910Cellular vaccine and method of inducing an immune response in a subject
#911COMBINATORIAL IMMUNOTHERAPY FOR PANCREATIC CANCER TREATMENT
#912Mature dendritic cell compositions and methods for culturing same
#913Reducing immune tolerance induced by PD-L1
#914High affinity NY-ESO T cell receptors
#915Cell surface coupling of nanoparticles
#916Tumor vaccination involving a humoral immune response against self-proteins
#917Multi-indication mRNA cancer immunotherapy
#918IMMUNE-CHECKPOINT INHIBITORS FOR USE IN THE TREATMENT OF BLOOD-BORNE CANCERS
#919Method for proliferation of antigen-specific T cells
#920IMMUNOTHERAPY OF CANCER USING GENETICALLY ENGINEERED GD2-SPECIFIC T CELLS
#921Claudin-6-specific immunoreceptors and T cell epitopes
#922Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
#923Compositions and methods for treating cancer
#924Compositions and methods for treating immunological dysfunction
#925CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
#926DNA vector and transformed tumor cell vaccines
#927Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
#928Composition and therapeutic anti-tumour vaccine
#929T-cell receptor-deficient T cell compositions
#930NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
#931Immunotherapy of cancer
#932Chimeric antigen receptors targeting B-cell maturation antigen
#933COMPOSITION AND METHODS OF GENOME EDITING OF B-CELLS
#934COMPOSITIONS AND METHODS FOR CANCER TREATMENT
#935Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells
#936Protein-cell conjugate, preparation method and use thereof
#937Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
#938COMPOSITE TISSUE CANCER VACCINE
#939Compositions and methods for treatment of cancer
#940CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS
#941Compound and method for vaccination and immunisation
#942Use of specific regulatory T-cells to induce immune tolerance
#943Compositions and methods for treatment of cancer
#944IMMUNOGENIC COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA
#945Methods of making chimeric antigen receptor-expressing cells
#946Engineered γδ T-cells
#947Antibodies to MUC16 and methods of use thereof
#948Compositions and methods for treatment of cancer
#949Method for selecting a permissive cell line for replicating avian viruses
#950Cells prepared by transient transfection and methods of use thereof
#951Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
#952Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
#953CD4 T cell vaccine and use thereof
#954Compositions and methods for treatment of cancer
#955Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
#956T cell receptor-deficient T cell compositions
#957Methods for treatment comprising an antibody that binds CD223 protein
#958Treatment of cancer using a CD33 chimeric antigen receptor
#959Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
#960Engineering and delivery of therapeutic compositions of freshly isolated cells
#961Anti-inflammatory, skin-regenerative, whitening, antioxidant, or wound-healing composition containing culture medium of ADSC-T cells in which T-antigen is introduced into adipose-derived stem cell as active ingredient
#962Treatment of cancer using a CD123 chimeric antigen receptor
#963Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
#964Treatment of cancer using a CLL-1 chimeric antigen receptor
#965GM-CSF and IL-4 conjugates, compositions, and methods related thereto
#966Tumor vaccine
#967Compositions and method for use of recombinant T cell receptors for direct recognition of tumor antigen
#968Effective generation of tumor-targeted T cells derived from pluripotent stem cells
#969Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
#970Compositions and methods for immunotherapy
#971Methods for inducing selective apoptosis
#972Reagent for gene-drug therapeutics
#973Multipotent adult stem cells and methods for isolation
#974Compositions and methods for immunotherapy
#975Compositions, methods, and kits for eliciting an immune response
#976Immune effector cells pre-infected with oncolytic virus
#977T cell receptor-deficient T cell compositions
#978Use of common γ chain cytokines for the visualization, isolation and genetic modification of memory T lymphocytes
#979Induced activation in dendritic cells
#980M971 chimeric antigen receptors
#981Treatment of cancer using anti-CD19 Chimeric Antigen Receptor
#982Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
#983Immunomodulating compositions and uses therefor
#984Strain-independent amplification of pathogens and vaccines thereto
#985Cell populations having immunoregulatory activity, method for isolation and uses
#986Cellular vaccine and method of inducing an immune response in a subject
#987Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
#988Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
#989Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
#990Methods for inducing migration by dendritic cells and an immune response
#991Tumor vaccination involving a humoral immune response against self-proteins
#992Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
#993Compositions and uses therefor
#994MODIFIED ERYTHROCYTE PRECURSOR CELLS AND USES THEREOF
#995Enhanced affinity T cell receptors and methods for making the same
#996Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
#997Compositions for treatment of cancer
#998Compositions for treatment of cancer
#999Alteration of cell membrane for new functions using IL-2 and streptavidin
#1000Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
#1001Canine babesiosis vaccine antigen
#1002Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
#1003METHOD FOR INDUCING IMMUNE TOLERANCE THROUGH TARGETTED GENE EXPRESSION
#1004CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
#1005Method and compositions for cellular immunotherapy
#1006Targeted disruption of T cell receptor genes using talens
#1007Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
#1008B7-H3 and B7-H4, novel immunoregulatory molecules
#1009Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
#1010Primary mesenchymal stem cells as a vaccine platform
#1011T-helper cell type 17 lineage-specific adjuvants, compositions and methods
#1012Antigen peptide and uses thereof
#1013Cell capable of expressing exogenous GITR ligand
#1014Method for proliferation of antigen-specific T cells
#1015Use of chimeric antigen receptor-modified T cells to treat cancer
#1016Dendritic cell co-stimulatory molecules
#1017Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
#1018Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
#1019Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
#1020Compositions and methods for treating cancer
#1021Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
#1022Mature dendritic cell compositions and methods for culturing same
#1023Engineering and delivery of therapeutic compositions of freshly isolated cells
#1024Immunotherapy of cancer using genetically engineered GD2-specific T cells
#1025Method of stimulating an immune response
#1026Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells
#1027HSV-1 epitopes and methods for using same
#1028Human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
#1029Methods for treatment of cancer
#1030Allogeneic cancer cell-based immunotherapy
#1031Compositions for treatment of cancer
#1032Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
#1033Use of chimeric antigen receptor-modified T-cells to treat cancer
#1034T-cell therapy to neurodegenerative diseases
#1035Compositions and methods for inducing migration by dendritic cells and an immune response
#1036Compositions, methods, and kits for eliciting an immune response
#1037Induced activation in dendritic cells
#1038Immunogenic compositions and methods for treating neoplasia
#1039Compositions and Methods for Enhancing Dendritic Cell Resistance to Bacterial Infection and for Enhancing the Mobility of Dendritic Cells for Dendritic Cell-Based Immunotherapy
#1040Antibodies to MUC16 and methods of use thereof
#1041Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
#1042Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
#1043Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
#1044METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY
#1045Virally infected hematopoietic cells and uses thereof
#1046Method for treating cancer with an antibody to CD223 protein
#1047Porcine CTLA-4 for xenograft-specific immunosuppression
#1048UNIVERSAL TUMOR CELL VACCINE FOR ANTI CANCER THERAPEUTIC AND PROPHYLACTIC UTILIZATION
#1049High affinity NY-ESO T cell receptors
#1050Tumor vaccination involving a humoral immune response against self-proteins
#1051TUMOR VACCINE
#1052KDR peptides and vaccines comprising the same
#1053Immune effector cells pre-infected with oncolytic virus
#1054IMMUNE MODULATORS RELATING TO FOXO3A
#1055PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
#1056KDR peptides and vaccines comprising the same
#1057T cell receptor-deficient T cell compositions
#1058Vectors and methods for long-term immune evasion to prolong tranplant viability
#1059MUTZ-3 dendritic cells
#1060IMP-3 OLIGOPEPTIDES AND VACCINES INCLUDING THE SAME
#1061Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
#1062Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection
#1063CONSENSUS SEQUENCE FOR INFLUENZA A VIRUS
#1064Compositions, methods, and kits for eliciting an immune response
#1065METHODS AND COMPOSITIONS FOR PRODUCING ANTIGENIC RESPONSES
#1066EXPRESSION OF HIV POLYPEPTIDES AND PRODUCTION OF VIRUS-LIKE PARTICLES
#1067Mature Dendritic Cell Compositions and Methods of Culturing Same
#1068Cytotoxic T lymphocyte
#1069Binding domain-immunoglobulin fusion proteins
#1070Alteration of cell membrane for new functions
#1071Immune Modulating Exosomes
#1072Method of identifying tumor associated antigens
#1073Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures
#1074Method of producing an antibody using a cancer cell
#1075Compositions and methods for treatment of cancer
#1076Ig-pCONSENSUS GENE VACCINATION PROTECTS FROM ANTIBODY-DEPENDENT IMMUNE PATHOLOGY IN AUTOIMMUNE DISEASE
#1077Methods for treating inflammation using B7-H4 polypeptides and fragments thereof
#1078DENDRITIC CELL CO-STIMULATORY MOLECULES
#1079DENDRITIC CELL CO-STIMULATORY MOLECULES
#1080T-helper cell type 17 lineage-specific adjuvants, compositions and methods
#1081CYTOKINE-EXPRESSING CELLULAR VACCINE COMBINATIONS
#1082Artificial cells
#1083Artificial cells
#1084Artificial cells
#1085Use of common γ chain cytokines for the visualization, isolation and genetic modification of memory T lymphocytes
#1086METHODS OF ENHANCING T CELL RESPONSIVENESS
#1087COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
#1088PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST DISSEMINATED CANDIDIASIS AND OTHER INFECTIOUS AGENTS
#1089TRANSFECTION OF BLOOD CELLS WITH MRNA FOR IMMUNE STIMULATION AND GENE THERAPY
#1090Compostition and therapeutic anti-tumour vaccine
#1091Human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
#1092IMMUNIZATION METHOD USING CANCER CELLS
#1093Universal GM-CSF Expressing Bystander Human Cell Line
#1094Cancer Treatment
#1095METHOD FOR TREATING SOLID TUMORS
#1096Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
#1097Methods for inducing selective apoptosis
#1098Compositions and methods for identifying antigens which elicit an immune response
#1099IMMUNOTHERAPEUTIC METHOD USING ALLO-CELLS WHICH CO-EXPRESS CD1d AND TARGET ANTIGEN
#1100Cancer immunotherapy
#1101Engineered cells expressing multiple immunomodulators and uses thereof
#1102IMMUNE RESPONSE INDUCING PREPARATIONS
#1103High affinity NY-ESO T cell receptors
#1104Tumor-derived Biological Antigen Presenting Particles
#1105Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
#1106Cell capable of expressing exogenous GITR ligand
#1107Allogeneic cancer cell-based immunotherapy
#1108Methods and compositions for inhibition of Treg cells
#1109Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
#1110BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
#1111Methods for the early diagnosis of ovarian cancer
#1112Device And Method For Transfecting Cells For Therapeutic Uses
#1113Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells
#1114Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
#1115Heat shock protein GP96 vaccination and methods of using same
#1116Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
#1117Method for determining the anti-tumor efficacy of monoclonal antibodies
#1118COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER
#1119TAPASIN AUGMENTATION FOR ENHANCED IMMUNE RESPONSE
#1120ANTIBODY CANCER IMMUNOTHERAPY
#1121Device and Method for Transfecting Cells for Therapeutic Use
#1122Dendritic Cells
#1123Artificial cells
#1124Methods of stimulating an immune response against prostate specific antigen
#1125Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
#1126Cell expressing complexes of IL-15 and IL-15Ralpha
#1127ADAPTER MOLECULE FOR THE DELIVERY OF ADENOVIRUS VECTORS
#1128Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface
#1129Artificial cells
#1130Artificial cells
#1131Expression of HIV polypeptides and production of virus-like particles
#1132Compositions and Methods for Treatment of Neoplastic Disease
#1133CHEMOKINE GENE-MODIFIED CELLS FOR CANCER IMMUNOTHERAPY
#1134Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
#1135Helper Virus-Free Herpesvirus Amplicon Particles and Uses Thereof
#1136High affinity NY-ESO T cell receptor
#1137Device and Method for Transfecting Cells for Therapeutic Use
#1138Combination of protein vaccine and mesenchymal stem cells for treating cancer
#1139Compositions and Methods for Cancer Treatment
#1140MICROBIAL DELIVERY SYSTEM
#1141Method for producing dendritic cells
#1142Therapeutic Cancer Antigens
#1143High affinity NY-ESO T cell receptors
#1144Increased T-cell tumor infiltration and eradication of metastases by mutant light
#1145VACCINE COMPOSITIONS
#1146Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine
#1147CD40 ligand-enhanced cells and methods of modulating an immune response to an antigen
#1148PD-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
#1149Device including bone cage and method for treatment of disease in a subject
#1150Device including bone cage and method for treatment of disease in a subject
#1151Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
#1152MODIFIED CELLS FOR TARGETED CELL TRAFFICKING AND USES THEREOF
#1153AVV Vectors and Methods
#1154Dendritic cell vaccine compositions and uses of same
#1155Suppression of immune response to factor VIII in hemophilia A patients
#1156Ras mutation and compositions and methods related thereto
#1157KDR peptides and vaccines comprising the same
#1158Antigen Presenting Cells
#1159HSV-1 epitopes and methods for using same
#1160METHODS OF SWITCHING THE PHENOTYPE OF T CELLS BY TRANSGENIC LINEAGE FACTOR FOXP3
#1161METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTOR ADAPTERS
#1162BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
#1163Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibody
#1164MODIFIED DENDRITIC CELLS HAVING ENHANCED SURVIVAL AND IMMUNOGENICITY AND RELATED COMPOSITIONS AND METHODS
#1165Generation of antigen specific T cells
#1166Tumor immunity
#1167Fusion molecule based on novel TAA variant
#1168Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
#1169Methods and reagents for decreasing clinical reaction to allergy
#1170Cancer vaccine based on brother of regulator of imprinted sites molecule (BORIS)
#1171ACTIVATED DUAL SPECIFICITY LYMPHOCYTES AND THEIR METHODS OF USE
#1172Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
#1173Porcine CTLA-4 for xenograft-specific immunosuppression
#1174TUMOR VACCINE
#1175MODIFIED HIV ENV POLYPEPTIDES
#1176Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization
#1177Methods and compositions relating to a vaccine against prostate cancer
#1178Novel Compositions and Uses Thereof
#1179Binding domain-immunoglobulin fusion proteins
#1180B cell-based vaccine loaded with the ligand of natural killer T cell and antigen
#1181Stably transformed bone marrow-derived cells and uses thereof
#1182FUSION MULTIVIRAL CHIMERIC ANTIGEN
#1183Method for producing antibodies
#1184COMPOSITION AND METHOD FOR TREATING ESOPHAGEAL DYSPLASIA
#1185Cell therapy method for the treatment of tumors
#1186Modified HIV Env polypeptides
#1187Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies
#1188PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST DISSEMINATED CANDIDIASIS AND OTHER INFECTIOUS AGENTS
#1189Tumor cell-based cancer immunotherapeutic compositions and methods
#1190Composition comprising an antisense sequence implicated in the regulation of angiogenesis
#1191Methods of stimulating an immune response against prostate specific antigen
#1192CELLULAR VACCINE
#1193Methods and compositions for transforming dendritic cells and activating cells
#1194Engineering and delivery of therapeutic compositions of freshly isolated cells
#1195KDR peptides and vaccines comprising the same
#1196Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
#1197Multipotent adult stem cells and methods for isolation
#1198Multipotent adult stem cells and methods for isolation
#1199Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector
#1200METHODS OF MHC CLASS II EPITOPE MAPPING, DETECTION OF AUTOIMMUNE T CELLS AND ANTIGENS, AND AUTOIMMUNE TREATMENT